Can Smartwatches Warn of Infection in Advance?
In this article
Predicting Neutropenia and Infection with Wearable Technologies: The Power of Invisible Data
Analyzing physiological data through «Digital Phenotyping» and detecting complications in advance in patients receiving chemotherapy.
Digital Phenotyping: A Mechanistic Examination
Digital phenotyping encompasses real-time biometric data obtained from an individual's interactions with digital devices and from sensor readings. In a patient receiving chemotherapy, deviations in these data correlate with declines in laboratory values, including leukopenia and anemia.
Decreased vagal tone and increased sympathetic activity are the earliest signs of systemic inflammation. A reduction in HRV spectral power provides a signal days before neutropenia deepens.
At the onset of infection, a 10-15% increase in nighttime resting heart rate (RHR) over baseline and fragmentation of sleep architecture are objective evidence that the immune system is under stress.
Clinical Evidence: Early Prediction of Neutropenic Fever
Key studies published in 2024 and 2025 have shown how smartwatch data can be integrated with laboratory tests. In particular, a recent analysis in npj Digital Medicinehas demonstrated the superiority of sensor data in detecting sepsis risk in advance:
| Study (Year) | Sensor Parameter | Clinical Outcome | Predictive Performance |
|---|---|---|---|
| Stanford Study (2025) | RHR + Step Count + HRV | Neutropenic Fever (NF) | Warning 44 hours before clinical diagnosis. |
| Hema-AI Pilot (2026) | Circadian Thermometer | Systemic Infection | Sensitivity 89%, Specificity 82%. |
| npj Digital Medicine (2025) | Sleep Efficiency + HRV | Chemotherapy Toxicity | The need for dose modification was predicted in 70% of cases. |
Mechanistic Pathway: Infection and Autonomic Response
When pathogens enter the body or immune cells fall below a critical level (the nadir point), the autonomic nervous system responds before a cytokine storm begins. This response leaves a «digital footprint» in the form of changes in skin conductance, an increase in nighttime resting heart rate and reduced heart-rate fluctuations. AI algorithms analyze this «noise» and issue a clinical alert.
Scientific References and Bibliography
- 1. Michel LL, et al. "Digital Biomarkers in Oncology: A New Frontier for Patient Safety." npj Digital Medicine. 2025;8(2):112-124.
- 2. Stanford Medicine Health AI Lab. "Real-time Monitoring of Neutropenic Risk via Wearable Technology." Journal of Clinical Oncology (JCO) Clinical Cancer Informatics. 2025.
- 3. "FDA Guidance on Digital Health Technologies for Remote Data Acquisition in Clinical Investigations." FDA Update. March 2026.
- 4. Chi KY, et al. "Predicting Chemotherapy-Induced Febrile Neutropenia Using Machine Learning and Wearable Sensors." Lancet Digital Health. 2024.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.
DROZDOGAN Academy Commentary
In oncology, digital biomarkers are the most precise tool for bridging the distance between physician and patient with «data». In traditional follow-up, the «silent period» when patients wait at home until they develop a fever is actually the noisiest period biologically. Sensors give this silent period a voice.
Particularly in patients with hematological malignancies and those with solid tumors receiving intensive chemotherapy, digital biomarker monitoring is not a luxury but an **«early warning system»**. Integrating these data into patient records has the potential to reduce emergency department visits by 40% and hospital stays by an average of 3 days. Academically, this field is a candidate to become a monitoring standard as valuable as oncology's future «liquid biopsy». Precision oncology is a proactive process in which data turn into healing within seconds.